ArmaGen is a privately held biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Our lead product candidates, AGT-182 for Hunter syndrome and AGT-181 for Hurler syndrome, are both funded. AGT-182 is currently in Phase 1 clinical trials, and AGT-181 is in Phase 2 clinical trials.

ArmaGen closed a $17 million series A financing in 2012 led by a consortium of top biopharmaceutical investment firms. The investor group is led by the Boehringer Ingelheim Venture Fund GmbH, and includes Shire plc, Takeda Ventures, Inc. and Mitsui Corporation Venture Partnership Technology Fund I, LLC.


Mitsui Global InvestmentBoehringer Ingelheim
ShireTakeda Ventures, Inc.

Corporate Fact Sheet